HEALTH● LOW2h ago · Sep 26, 2026, 1:54 PM
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder
Seeking Alpha Tech · global
Two companies, Mirum and Incyte, have received approval for a drug named zilurgisertib, intended to treat a rare bone disorder. This approval marks a significant development in the treatment options available for patients with this condition.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH37m agoSome states are taking a tougher stance as Medicaid work requirements kick inThe Independent WorldHEALTH1h agoCaro Trippar broke down when telling how her breast cancer treatment is evolving: “I thought I would never make it”ClarínHEALTH1h agoAI should complement radiologists, says AIIMS-Mangalagiri chief at AP IRIA conferenceThe HinduHEALTH2h ago26/9 in Nieuwsuur: Ebola in Congo • The future of the UNNOS Buitenland